The in vitro diagnostics market is expected to experience significant growth due to the increasing incidence of sexually transmitted infections (STIs) such as syphilis, gonorrhea, chlamydia, HIV, and HPV. According to the World Health Organization (WHO), there are approximately 376 million new cases of syphilis, gonorrhea, chlamydia, and trichomoniasis recorded annually. Additionally, over 500 million people are estimated to have genital herpes simplex virus (HSV), and around 300 million women have human papillomavirus (HPV) infection, which is the leading cause of cervical cancer. The total number of new cases of HIV was found to be 1.5 million in 2020. The increasing prevalence of these STIs is expected to provide the in vitro diagnostics market with a large target population. The market is also expected to benefit from the growing demand for rapid and on-site testing solutions, as well as continuous advancements in diagnostic technologies, such as molecular diagnostics, immunoassays, and point-of-care testing.
Technological advancements related to accuracy, portability, and cost-effectiveness are expected to drive the market over the forecast period. Key players are expanding their test portfolios, which include qPCR instruments, by investing in R&D to develop diagnostic kits that can identify emerging diseases or by entering into agreements with other kit manufacturing companies. In April 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics, Inc. for USD 24.05 per share in cash and holds around 82.89% of the total shares of the company. GenMark Diagnostics, Inc. has proprietary technologies, such as eSensor XT-8 and ePlex, that can be utilized in developing infectious disease tests, including bloodstream infections. Furthermore, the development and commercialization of advanced products, such as multiplex PCR products and next-generation HIV testing kits, enable physicians to timely distinguish and diagnose a range of STIs and provide appropriate treatment. Seegene, Inc., a South Korea-based diagnostic company, provides a wide portfolio of Allplex, Anyplex, and Seeplex products that detect various causative agents. For instance, the Allplex STI/BV Panel Assay can distinguish 28 causative agents in a single test. In July 2021, Danaher (Cepheid) received CE marking for its next-generation extended coverage tests for HIV testing in patients, which include Xpert HIV-1 Viral Load XC and Xpert HIV-1 Qual XC. The availability of an at-home collection and self-testing kits reduces patient visits to clinics and promotes patint discretion as well.
The increasing number of government initiatives aimed at containing the STD epidemic, including regular screening guidelines and vaccination coverage for various diseases, is expected to have a significant impact on the in vitro diagnostics market. These initiatives are designed to reduce the overall disease burden in the region, which may have an adverse effect on market growth. For example, the vaccination coverage for diseases such as HPV and herpes zoster virus has been increasing, which is expected to contribute to the reduction of disease prevalence. However, the availability of at-home collection and self-testing kits is also reducing patient visits to clinics and promoting discretion among patients, which may offset the potential impact of government initiatives on market growth.
This section will provide insights into the contents included in this STD diagnostics market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Market drivers and restraints
Key market opportunities prioritized
Latest strategic developments
Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member